AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28903122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (Q4W)
Number of subjects: 3
Study 28903122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 28903122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 3
Study 28903122 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 3
Study 24251557 — intervention group
Group type: EXPERIMENTAL
Intervention: Weishi Bitong Xifang fumigation
Number of subjects: 100
Study 24251557 — intervention group
Group type: COMPARATOR
Intervention: Voltaren emulgel
Number of subjects: 100
Study 24793535 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of rhPTH(1‐34) (10, 20, 30, 40, 50, or 60 μg)
Number of subjects: 72
Study 24793535 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose of rhPTH(1‐34) (10 and 20 μg once daily for 7 consecutive days)
Number of subjects: 72
Study 24793535 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of rhPTH(1‐34) (10, 20, or 40 μg)
Number of subjects: 72
Study 24793535 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose of rhPTH(1‐34) (20 μg)
Number of subjects: 72
Study 22551909 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/d plus OAT with warfarin (C + OAT)
Number of subjects: 341
Study 22551909 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy with clopidogrel 75 mg/d plus aspirin 100 mg/d (C + ASA)
Number of subjects: 341
Study 22551909 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 341
Study 19527382 — intervention group
Group type: EXPERIMENTAL
Intervention: External aortic compression device (EACD) with traditional management
Number of subjects: 300
Study 19527382 — intervention group
Group type: COMPARATOR
Intervention: Traditional management alone
Number of subjects: 300
Study 19527382 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional management)
Number of subjects: 300
Study 19527382 — intervention group
Group type: EXPERIMENTAL
Intervention: External aortic compression device (EACD)
Number of subjects: 300
Study 17853393 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOX (5-fluorouracil, leucovorin plus oxaliplatin)
Number of subjects: 1857
Study 17853393 — intervention group
Group type: COMPARATOR
Intervention: FL (5-fluorouracil and leucovorin)
Number of subjects: 1857
Study 17853393 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOX
Number of subjects: 1857
Study 17853393 — intervention group
Group type: COMPARATOR
Intervention: FL
Number of subjects: 1857
Study 15457467 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg twice a day (n = 104)
Number of subjects: 207
Study 15457467 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 103)
Number of subjects: 207
Study 11404671 — intervention group
Group type: EXPERIMENTAL
Intervention: ORAL (0.45% NaCl) equal to 50% of prior dehydration
Number of subjects: 8
Study 11404671 — intervention group
Group type: EXPERIMENTAL
Intervention: IV (0.45% NaCl) equal to 50% of prior dehydration
Number of subjects: 8
Study 11404671 — intervention group
Group type: COMPARATOR
Intervention: Control (CON), no fluid trial
Number of subjects: 8
Study 10791876 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDSVAX (MN) vaccine (300 microg of MN-rgp120 in alum)
Number of subjects: 33
Study 10791876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alum)
Number of subjects: 33
Study 7598995 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subnitrate (BSN) for 8 weeks
Number of subjects: 66
Study 7598995 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) for 8 weeks
Number of subjects: 66
Study 7598995 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (control group) for 4 weeks
Number of subjects: 66
Study 2334624 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 50
Study 306010 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole gut irrigation (w.g.i.)
Number of subjects: 163
Study 306010 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole gut irrigation (w.g.i.) for removal of blood from the intestinal tract
Number of subjects: 163
Study 306010 — intervention group
Group type: COMPARATOR
Intervention: Elemental diet
Number of subjects: 163
Study 31686817 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized DPX-loaded nanoparticles (30 mg single oral dose)
Number of subjects: 0
Study 31686817 — intervention group
Group type: COMPARATOR
Intervention: Marketed DPX tablet
Number of subjects: 0
Study 29099839 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 751
Study 29099839 — intervention group
Group type: COMPARATOR
Intervention: Condom use during first intercourse
Number of subjects: 751
Study 25892169 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute sessions of prolonged exposure (PE)
Number of subjects: 39
Study 25892169 — intervention group
Group type: COMPARATOR
Intervention: 90-minute sessions of prolonged exposure (PE)
Number of subjects: 39
Study 23398146 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex Luminex bead assay for HNA allele detection
Number of subjects: 140
Study 21553078 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary carbohydrate, glycemic index (GI), glycemic load (GL)
Number of subjects: 30482
Study 19609225 — intervention group
Group type: EXPERIMENTAL
Intervention: Black cohosh
Number of subjects: 89
Study 19609225 — intervention group
Group type: EXPERIMENTAL
Intervention: Red clover
Number of subjects: 89
Study 19609225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 19609225 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE/MPA
Number of subjects: 89
Study 17597497 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise intervention (one hour per week for 12 months)
Number of subjects: 47
Study 17597497 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 47
Study 15531304 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication (nonselective beta-blocker or prostaglandin analog)
Number of subjects: 689
Study 11171592 — intervention group
Group type: EXPERIMENTAL
Intervention: 2%FAT
Number of subjects: 7
Study 11171592 — intervention group
Group type: COMPARATOR
Intervention: 22%FAT
Number of subjects: 7
Study 10093291 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent Hib and hepatitis B vaccine (7.5 micrograms of PRP bound to 125 micrograms of OMP and 5 micrograms of recombinant hepatitis B surface antigen)
Number of subjects: 0
Study 10093291 — intervention group
Group type: COMPARATOR
Intervention: Monovalent controls (Hib and hepatitis B)
Number of subjects: 0
Study 9631980 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril 20 to 40 mg/day
Number of subjects: 60
Study 9631980 — intervention group
Group type: COMPARATOR
Intervention: no benazepril
Number of subjects: 60
Study 2667601 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin (3 X 10(6) iu, twice daily)
Number of subjects: 5
Study 2667601 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin
Number of subjects: 5
Study 770082 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg azapropazone per day
Number of subjects: 50
Study 770082 — intervention group
Group type: COMPARATOR
Intervention: 100 mg indomethacin per day
Number of subjects: 50
Study 31286158 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrotherapy, manual therapy, and pelvic floor muscle exercises
Number of subjects: 64
Study 31286158 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 64
Study 28856399 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing-assisted surgery
Number of subjects: 40
Study 28856399 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 40
Study 28856399 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing model (PLA)
Number of subjects: 40
Study 28856399 — intervention group
Group type: COMPARATOR
Intervention: 2D imaging data
Number of subjects: 40
Study 24941950 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-Based Feeding (VBF)
Number of subjects: 63
Study 24941950 — intervention group
Group type: COMPARATOR
Intervention: Rate-Based Feeding (RBF)
Number of subjects: 63
Study 23294500 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice a day
Number of subjects: 399
Study 23294500 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice a day
Number of subjects: 399
Study 23294500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 21752899 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/d for 6 weeks)
Number of subjects: 16
Study 21752899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18997444 — intervention group
Group type: EXPERIMENTAL
Intervention: epalrestat (150 mg/day)
Number of subjects: 21
Study 18997444 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study 17144779 — intervention group
Group type: EXPERIMENTAL
Intervention: Various strategies for minimizing NSAID risks including low dosages, modified-release and enteric-coated NSAIDs, cyclooxygenase-2-selective inhibitors, monitoring for side effects, and treatments to minimize side effects.
Number of subjects: 0
Study 15165772 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency sinus excision
Number of subjects: 30
Study 15165772 — intervention group
Group type: COMPARATOR
Intervention: Excision and marsupialization
Number of subjects: 30
Study 12182036 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mCi
Number of subjects: 220
Study 12182036 — intervention group
Group type: COMPARATOR
Intervention: 60 mCi
Number of subjects: 220
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR monotherapy 120 mg
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR monotherapy 180 mg
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR monotherapy 240 mg
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril monotherapy 0.5 mg
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril monotherapy 2 mg
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril monotherapy 8 mg
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 0.5/120 mg
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 0.5/180 mg
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 0.5/240 mg
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 2/120 mg
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 2/180 mg
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 2/240 mg
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 8/120 mg
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 8/180 mg
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril/Verapamil SR combination 8/240 mg
Number of subjects: 746
Study 9231890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 746
Study 9231890 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono- and combination therapy
Number of subjects: 746
Study 7965901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (50 mg once a day for 2 weeks)
Number of subjects: 45
Study 7965901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole plus chlorhexidine (chlorhexidine applied twice a day for 2 weeks)
Number of subjects: 45
Study 7965901 — intervention group
Group type: COMPARATOR
Intervention: New dentures (no medication)
Number of subjects: 45
Study 3283085 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-beam radiotherapy (2 fractions a week of neutrons, 3 fractions a week of photons to a total RBE-adjusted dose of 50 Gy over 5 weeks plus intracavitary applications or external mixed-beam boost)
Number of subjects: 146
Study 3283085 — intervention group
Group type: COMPARATOR
Intervention: Photons only (50 Gy in 25 fractions over 5 weeks plus intracavitary applications or external-beam boost)
Number of subjects: 146
Study 31310080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative local mitomycin-C (MMC)
Number of subjects: 40
Study 31310080 — intervention group
Group type: COMPARATOR
Intervention: Standard vasovasostomy (Control)
Number of subjects: 40
Study 29043411 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐DM1 (ado-trastuzumab emtansine) administered weekly or every three weeks
Number of subjects: 136
Study 29043411 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐DM1 (ado-trastuzumab emtansine)
Number of subjects: 136
Study 25345751 — intervention group
Group type: EXPERIMENTAL
Intervention: PtCr-EES
Number of subjects: 100
Study 25345751 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation
Number of subjects: 100
Study 22980443 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 439
Study 21636241 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonexpert feedback (Group B)
Number of subjects: 18
Study 21636241 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert feedback (Group C)
Number of subjects: 18
Study 21636241 — intervention group
Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 18
Study 19486119 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 93
Study 19486119 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 93
Study 16843170 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheolytic thrombectomy (RT) as an adjunct to primary percutaneous coronary intervention (PCI)
Number of subjects: 480
Study 16843170 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (PCI) alone
Number of subjects: 480
Study 15931325 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors in postmenopausal women with invasive or intraductal breast cancer
Number of subjects: 0
Study 15931325 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxanes for patients with positive nodes and in the neoadjuvant setting
Number of subjects: 0
Study 15931325 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted molecular therapies such as trastuzumab and bisphosphonates
Number of subjects: 0
Study 10802838 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction (Trach Care MAC)
Number of subjects: 175
Study 10802838 — intervention group
Group type: COMPARATOR
Intervention: Open suction
Number of subjects: 175
Study 9355890 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise and low-fat diet (intervention group n=40)
Number of subjects: 90
Study 9355890 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=50)
Number of subjects: 90
Study 8320430 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid function and volume monitoring during gestation in euthyroid pregnant women with excessive thyroidal stimulation.
Number of subjects: 0
Study 2867985 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 20
Study 2867985 — intervention group
Group type: COMPARATOR
Intervention: Antiacids
Number of subjects: 20
Study 29266633 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture/stretching plus physiotherapy (microwave diathermy and myofascial release)
Number of subjects: 44
Study 29266633 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture/stretching
Number of subjects: 44
Study 27003390 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation program conducted weekly for 5 weeks in 60-min sessions
Number of subjects: 118
Study 27003390 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation program
Number of subjects: 118
Study 27003390 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 118
Study 25023786 — intervention group
Group type: EXPERIMENTAL
Intervention: WLC + PDD with hexaminolevulinate
Number of subjects: 151
Study 25023786 — intervention group
Group type: COMPARATOR
Intervention: WLC alone (control)
Number of subjects: 151
Study 22960764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib/basiliximab
Number of subjects: 15
Study 22960764 — intervention group
Group type: COMPARATOR
Intervention: CNI/basiliximab
Number of subjects: 15
Study 22960764 — intervention group
Group type: COMPARATOR
Intervention: CNI (tacrolimus)
Number of subjects: 15
Study 19637333 — intervention group
Group type: EXPERIMENTAL
Intervention: EcN plus mesalamine (1500 mg twice a day)
Number of subjects: 48
Study 19637333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 18362764 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless learning (EL)
Number of subjects: 18
Study 18362764 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐instruction training (SIT)
Number of subjects: 18
Study 18362764 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 18
Study 15849057 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-IPV
Number of subjects: 416
Study 15849057 — intervention group
Group type: COMPARATOR
Intervention: DTPa + IPV
Number of subjects: 416
Study 12852099 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral continuous‐combined regimen of conjugated estrogens + medroxyprogesterone acetate
Number of subjects: 0
Study 10673888 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg orally once daily for 4 days
Number of subjects: 7
Study 10673888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8598355 — intervention group
Group type: EXPERIMENTAL
Intervention: ERT + Mito (IV 12.5 mg/m(2) during the first and fourth week of ERT)
Number of subjects: 327
Study 8598355 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU (i.v. 200 mg/m(2) every 6 weeks)
Number of subjects: 327
Study 8598355 — intervention group
Group type: COMPARATOR
Intervention: 6-mercaptopurine (6-MP, 750 mg/m(2) IV daily for 3 days every six weeks)
Number of subjects: 327
Study 8598355 — intervention group
Group type: COMPARATOR
Intervention: ERT alone (61.2 Gy)
Number of subjects: 327
Study 8598355 — intervention group
Group type: COMPARATOR
Intervention: ERT + Mito
Number of subjects: 327
Study 8598355 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine/6-MP
Number of subjects: 327
Study 1927314 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser ridge
Number of subjects: 271
Study 1927314 — intervention group
Group type: COMPARATOR
Intervention: No laser ridge (Control)
Number of subjects: 271
Study 6372066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 1 g/day
Number of subjects: 69
Study 6372066 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine, 50 mg/day
Number of subjects: 69
Study 6372066 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 69
Study 31046885 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning accelerometer
Number of subjects: 333
Study 31046885 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cut-point accelerometer
Number of subjects: 333
Study 31046885 — intervention group
Group type: COMPARATOR
Intervention: Cut-point accelerometer
Number of subjects: 333
Study 31046885 — intervention group
Group type: COMPARATOR
Intervention: Self-report
Number of subjects: 333
Study 29023550 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.08% BAC)
Number of subjects: 20
Study 29023550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.00% BAC)
Number of subjects: 20
Study 26522498 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving reminiscence activities
Number of subjects: 321
Study 26522498 — intervention group
Group type: EXPERIMENTAL
Intervention: Identity reminiscence activities
Number of subjects: 321
Study 26522498 — intervention group
Group type: COMPARATOR
Intervention: Bitterness revival reminiscence activities
Number of subjects: 321
Study 26522498 — intervention group
Group type: COMPARATOR
Intervention: Control condition (any memory from their past)
Number of subjects: 321
Study 25156987 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of depression (score ≥7 on the Short‐CARE depression scale)
Number of subjects: 613
Study 25156987 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal performance on executive function test and depression (n=57)
Number of subjects: 613
Study 25156987 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal performance on verbal recall test and depression (n=43)
Number of subjects: 613
Study 25156987 — intervention group
Group type: COMPARATOR
Intervention: Participants without depression
Number of subjects: 613
Study 23092239 — intervention group
Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 17938
Number of subjects: 18
Study 23092239 — intervention group
Group type: COMPARATOR
Intervention: L. plantarum 299v
Number of subjects: 18
Study 23092239 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli lozenges (L. reuteri DSM 17938 and ATCC PTA 5289)
Number of subjects: 18
Study 23092239 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 18
Study 23092239 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (probiotic lozenges)
Number of subjects: 18
Study 23092239 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo lozenges)
Number of subjects: 18
Study 20804230 — intervention group
Group type: COMPARATOR
Intervention: Community health worker interventions
Number of subjects: 53
Study 17240231 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate 40 mg vaginally
Number of subjects: 200